&w=3840&q=100)
Why did Natco Pharma's share price slip 3% in trade today? Details here
Around 10:20 AM, Natco Pharma shares continued to trade lower, down 1.64 per cent at ₹897.60 per share. In comparison, BSE Sensex was trading 0.28 per cent higher at 81,348.53 levels.
Why did Natco Pharma share price slip in trade?
Natco Pharma shares slipped in trade after the company said that the United States Food and Drug Administration (USFDA) has issued one (1) observation in the Form-483 for its API manufacturing plant in Mekaguda, Hyderabad. However, Natco Pharma believes that the observation is procedural in nature
Natco Pharma further said that it is confident to address this observation comprehensively.
The US drug authority had conducted the inspection from June 9 to June 13, 2025. Catch Stock Market Updates Today LIVE
Natco Pharma results
Natco Pharma's consolidated profit after tax (PAT) rose to ₹406 crore in the March quarter of FY25, from ₹386.3 crore in the March quarter of FY24.
The company's revenue from operations, or topline, surged to ₹1,287.3 crore in Q4FY25, from ₹1,110.3 crore in Q4FY24.
At the operating level, earnings before interest, tax, depreciation and amortisation (Ebitda) soared to ₹614.4 crore in the March quarter of FY25, from ₹539.3 crore in the March quarter of FY24. However, Ebitda margin squeezed to 47.7 per cent in Q4FY25, from 48.6 per cent a year ago.
About Natco Pharma
Natco Pharma, based in Hyderabad, India, is a research-driven company engaged in the development, manufacturing, and distribution of generic and branded pharmaceuticals, specialty drugs, active pharmaceutical ingredients (APIs), and crop protection products.
A leading player in oncology and targeted therapies in the domestic market, Natco Pharma focuses on niche, limited-competition molecules in the US.
Its manufacturing facilities are approved by major regulatory bodies including the US FDA, ANVISA (Brazil), Health Canada, and the WHO, serving over 50 international markets.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
5 hours ago
- Time of India
Sun Pharma says working towards full regulatory resolution at 3 plants facing USFDA action
Drug major Sun Pharmaceutical Industries aims to bolster compliance across its manufacturing operations and work towards achieving full regulatory resolution at the three facilities facing USFDA action, according to Chairman and MD Dilip Shanghvi. In his address to shareholders in its annual report for 2024-25, Shanghvi said the company is facing US Food and Drug Administration (USFDA) compliance-related issues at three of its facilities. The company is facing an import alert for the Halol facility and also is in receipt of non-compliance letter for the Mohali facility , he stated. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Shape your journey in the unforgiving desert world of Arrakis! Shop Now Undo Additionally, the company's Dadra facility was accorded an Official Action Indicated (OAI) status in FY24, he noted. "We have completed the implementation of Corrective and Preventive Action (CAPA) in the Halol facility, which is currently awaiting USFDA inspection, and we are in the process of implementing CAPA at the Mohali and Dadra facilities," he added. Live Events Besides these three, all facilities remain compliant with global regulatory standards, including those of the US FDA, Shanghvi said. On the business front, he noted the company expects its R&D investment to be in the range of 6-8 per cent of sales in the current financial year, with enhanced focus on speciality products. The company aims to expand its product pipeline of global speciality products, he added. "Our R&D spend in FY26 is likely to be in the range of 6-8 per cent of sales, with increased spending expected on speciality products," Shanghvi stated. The Mumbai-based drug major invested USD 154 million on speciality products R&D in FY25. Sun Pharma reported consolidated revenues of Rs 52,041 crore in FY25, with the share of global speciality business increasing from 18 per cent in FY24 to 20 per cent in FY25 sales. The company sells speciality products like Ilumya, Winlevi, Cequa and Odomzo across markets. "We anticipate mid to high single-digit consolidated topline growth in FY26, and expect our global speciality business to continue on its growth path," Shanghvi said. Elaborating on the focus areas, he said the company plans to prepare the business for potential disruptions arising from tariffs and geopolitical issues. The company would also continue to focus on cost and operational efficiency, he added.
Time of India
9 hours ago
- Time of India
Marathon Nxtgen Realty bulk deal: Nomura sells over 4 lakh shares worth Rs 29 crore
Nomura on Monday sold nearly 4.4 lakh shares in Mumbai-based Marathon Nxtgen Realty in a bulk deal worth over Rs 29 crore. Nomura sold shares via Nomura Singapore at a price of Rs 670.11 per share which was marginally higher from the Friday closing price. The stock witnessed another bulk deal from NECTA Bloom VCC - NECTA Bloom One where 3.6 lakh shares were offloaded at a deal size of Rs 24 crore. Marathon Nxtgen Realty is a five decade old company based out of Mumbai and claims to have completed over 100 projects in the city. With a market capitalisation of Rs 4,664.15, the company's stock has slightly outperformed the Nifty with over 8% returns in the past 12 months versus 4.7% by the latter in the same period. On the year-to-date basis, this smallcap stock has delivered 15% returns. Today the shares of Marathon Nxtgen Realty closed at Rs 691.80, gaining by Rs 23.85 or 3.57%. Live Events India headline indices Nifty and Sensex today ended flat witnessing selling pressure in the IT stocks ahead of the earnings season which begins on Thursday with the announcement of Q1FY26 results by IT bellwether Tata Consultancy Services (TCS). Markets remain cautious primarily for two big factors -- the deadline of Trump's tariff pause ends Thursday and release of Federal Reserve's June FOMC minutes. Also Read: Q1 earnings season kicks-off with TCS results on July 10. Check key dates for HDFC Bank, ICICI Bank & more Globally, the stock markets will keep an eye on the commentary on the US economy and inflation and will set the tone for the next policy which begins on July 29. Nifty today ended the session at 25,461.30, while the BSE Sensex settled at 83,442.50, gaining 9.61 points.
Economic Times
10 hours ago
- Economic Times
Marathon Nxtgen Realty bulk deal: Nomura sells over 4 lakh shares worth Rs 29 crore
Nomura on Monday sold nearly 4.4 lakh shares in Mumbai-based Marathon Nxtgen Realty in a bulk deal worth over Rs 29 crore. Nomura sold shares via Nomura Singapore at a price of Rs 670.11 per share which was marginally higher from the Friday closing price. ADVERTISEMENT The stock witnessed another bulk deal from NECTA Bloom VCC - NECTA Bloom One where 3.6 lakh shares were offloaded at a deal size of Rs 24 crore. Marathon Nxtgen Realty is a five decade old company based out of Mumbai and claims to have completed over 100 projects in the city. With a market capitalisation of Rs 4,664.15, the company's stock has slightly outperformed the Nifty with over 8% returns in the past 12 months versus 4.7% by the latter in the same period. On the year-to-date basis, this smallcap stock has delivered 15% the shares of Marathon Nxtgen Realty closed at Rs 691.80, gaining by Rs 23.85 or 3.57%. India headline indices Nifty and Sensex today ended flat witnessing selling pressure in the IT stocks ahead of the earnings season which begins on Thursday with the announcement of Q1FY26 results by IT bellwether Tata Consultancy Services (TCS). Markets remain cautious primarily for two big factors -- the deadline of Trump's tariff pause ends Thursday and release of Federal Reserve's June FOMC minutes. ADVERTISEMENT Also Read: Q1 earnings season kicks-off with TCS results on July 10. Check key dates for HDFC Bank, ICICI Bank & more Globally, the stock markets will keep an eye on the commentary on the US economy and inflation and will set the tone for the next policy which begins on July 29. ADVERTISEMENT Nifty today ended the session at 25,461.30, while the BSE Sensex settled at 83,442.50, gaining 9.61 points. (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times) (You can now subscribe to our ETMarkets WhatsApp channel)
